Astrazeneca plc, of London, said it entered an agreement with Cilag GmbH International, an affiliate of New Brunswick, N.J.-based Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua (budesonide) outside the U.S. Read More
Biotech IPOs were sluggish in the third quarter, with only seven companies successfully completing their offerings on U.S. exchanges, raising a collective $396 million in the process, according to BioWorld analysis. Read More
Clovis Oncology Inc. (NASDAQ:CLVS) shares fell 17.8 percent on Friday as investors wrestled with the competitive implications of data submitted in rucaparib's new drug application (NDA) and presented at the European Society for Medical Oncology congress in Copenhagen. p> Read More
LONDON – The pressure on pharma companies over drug pricing has intensified with a proposal for an EU-wide initiative to improve access to medicines through measures including increased transparency and cooperation on pricing negotiations, "in order to achieve fair prices for medicines." Read More
Alexion Pharmaceuticals Inc., of New Haven, Conn., presented new long-term data from an ongoing, open-label extension of the pivotal phase III ARISE trial of Kanuma (sebelipase alfa) in children and adults with lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease. Read More
Idera Pharmaceuticals Inc., of Cambridge, Mass., said it priced a public offering of 25 million shares at $2 apiece for gross proceeds of $50 million. Read More
Exelixis Inc., of South San Francisco, said collaborator Genentech Inc., of South San Francisco, a member of Roche Holding AG, presented preliminary results from a phase Ib trial evaluating the triple combination of cobimetinib, Zelboraf (vemurafenib) and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma. Read More
Earlier this year, the quiet joining of two recent San Diego-based startups led to the creation of Oncternal Therapeutics Inc., an oncology-focused firm boasting two potentially first-in-class drugs, both of which already have entered the clinic. Read More
Formation of amyloid bodies is a widespread coping mechanism to stress in cells, and should be considered a normal organizational feature, scientists from the University of Miami Miller School of Medicine have argued. Read More
HONG KONG – Looking to leverage the "huge opportunity" in the ever-promising markets in Asia-Pacific, Mundipharma Pharmaceutical Co. Ltd. will launch Betadine, its first consumer health product in China, over the coming quarter. Read More
HONG KONG – A University of Hong Kong (HKU) phase II trial has shown that a drug derived from an herb used in traditional Chinese medicine to treat acute myeloid leukemia (AML) has helped patients with an aggressive treatment-refractory form of AML to achieve remission. Read More
